These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 458947)
1. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW J Urol; 1979 Jun; 121(6):763-5. PubMed ID: 458947 [TBL] [Abstract][Full Text] [Related]
2. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW Trans Am Assoc Genitourin Surg; 1978; 70():69-71. PubMed ID: 753026 [TBL] [Abstract][Full Text] [Related]
3. New steroidal alkylating agents in advanced stage D carcinoma of the prostate. Mittelman A; Catane R; Murphy GP Cancer Treat Rep; 1977; 61(2):307-10. PubMed ID: 872134 [TBL] [Abstract][Full Text] [Related]
4. Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine. Catane R; Kaufman J; Mittelman A; Murphy GP J Urol; 1977 Mar; 117(3):332-5. PubMed ID: 839597 [TBL] [Abstract][Full Text] [Related]
5. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. Soloway MS; deKernion JB; Gibbons RP; Johnson DE; Loening SA; Pontes JE; Prout GR; Schmidt JD; Scott WW; Chu TM; Gaeta JF; Slack NH; Murphy GP J Urol; 1981 May; 125(5):664-7. PubMed ID: 7230336 [TBL] [Abstract][Full Text] [Related]
6. Prednimustine for prostate cancer therapy. Slack NH; Murphy GP Compr Ther; 1979 Sep; 5(9):54-7. PubMed ID: 487742 [No Abstract] [Full Text] [Related]
7. A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer. Løber J; Mouridsen HT; Christiansen IE; Dombernowsky P; Mattsson W; Rørth M Cancer; 1983 Nov; 52(9):1570-6. PubMed ID: 6352005 [TBL] [Abstract][Full Text] [Related]
8. A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. Soloway MS; Beckley S; Brady MF; Chu TM; deKernion JB; Dhabuwala C; Gaeta JF; Gibbons RP; Loening SA; McKiel CF; McLeod DG; Pontes JE; Prout GR; Scardino PT; Schlegel JU; Schmidt JD; Scott WW; Slack NH; Murphy GP J Urol; 1983 Jan; 129(1):56-61. PubMed ID: 6338251 [TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone. Ideström K; Kimby E; Björkholm M; Mellstedt H; Engstedt L; Gahrton G; Johansson B; Killander D; Robérts KH; Stalfelt AM; Udén AM; Wadman B; Wählby S Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1117-23. PubMed ID: 6897633 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031). Beckley S; Wajsman LZ; Slack NH; Murphy GP Urology; 1981 May; 17(5):446-8. PubMed ID: 7015669 [TBL] [Abstract][Full Text] [Related]
11. The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. Gibbons RP; Beckley S; Brady MF; Chu TM; Dekernion JB; Dhabuwala C; Gaeta JF; Loening SA; McKiel CF; McLeod DG; Pontes JE; Prout GR; Scardino PT; Schlegel JU; Schmidt JD; Scott WW; Slack NH; Soloway MS; Murphy GP J Surg Oncol; 1983 Jun; 23(2):133-42. PubMed ID: 6343726 [TBL] [Abstract][Full Text] [Related]
12. Clinical experience with estramustine phosphate and predinimustine, two steroidal alkylating agents compounds [proceedings]. Catane R Cancer Treat Rep; 1978 Aug; 62(8):1264-5. PubMed ID: 688269 [No Abstract] [Full Text] [Related]
13. Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate. Benson RC; Wear JB; Gill GM J Urol; 1979 Apr; 121(4):452-4. PubMed ID: 439216 [TBL] [Abstract][Full Text] [Related]
14. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt). Vahlensieck W; Wegner G Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018 [TBL] [Abstract][Full Text] [Related]
17. Observations of prolonged use of oral Emcyt in prostatic cancer patients. Slack NH; Brady MF; Murphy GP Urology; 1982 Nov; 20(5):515-23. PubMed ID: 6755858 [TBL] [Abstract][Full Text] [Related]
18. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer. de Kernion JN; Murphy GP; Priore R Urology; 1988 Apr; 31(4):312-7. PubMed ID: 3281365 [TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of estramustine phosphate in the treatment of patients with advanced breast cancers]. Wada T; Morikawa E; Houjou T; Kadota K; Mori N; Matsunami N; Watatani M; Yasutomi M Gan To Kagaku Ryoho; 1990 Sep; 17(9):1901-4. PubMed ID: 2393306 [TBL] [Abstract][Full Text] [Related]
20. Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer. Beckley S; Wajsman Z; Maeso E; Pontes E; Murphy G Urology; 1981 Dec; 18(6):592-5. PubMed ID: 7198328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]